ALS Center of Excellence

Pranger ALS Clinic

  • Home
  • About
    • What Is ALS?
    • Scott L. Pranger
    • National Advisory Board
    • Faculty & Staff
    • ALS Center of Excellence Brochure
  • Clinic
    • Services
    • Your Visit to the ALS Clinic
    • Patient Portal
    • Durable Medical Equipment
    • Frequently Asked Questions
  • Research
    • Clinical Trials
    • Observational Studies
    • Participate in Research at U-M
  • News
  • Patient Care Guide
    • Living with ALS
    • Nutrition
    • Patient & Family Support
  • Contact
  • NeuroNetwork
  • Make A Gift

Latest News

ALS Risk Higher Among Production Workers

… [Read More...]

“Research Into Preventing ALS…”

… [Read More...]

portrait of Dr. Eva Feldman in her lab

Dr. Feldman Given Highest University of Michigan Honor

… [Read More...]

Multidisciplinary Team Publishes Paper on ALS Occupational Risk

… [Read More...]

The ANA Q&A: Dr. Eva Feldman on ALS

… [Read More...]

Early Treatment with New ALS Drug Combination Improved Survival

October 16, 2020

An open label extension shows additional benefit from a drug currently being tested for patients with Lou Gehrig’s disease.

from the M Health Lab Blog by Haley Otman

Follow up data shows that not only did a new drug help slow the effects of amyotrophic lateral sclerosis, or ALS, on patients’ day-to-day ability to function, but it may also keep patients alive longer when they start it early on in their disease course.

After taking part in a clinical trial for the drug known as AMX0035, 92% of the participants elected to use the drug in an open-label extension study. The people who had originally been randomized to take the drug had a 44% lower risk of death over a period up to three years compared to those who were originally randomized to placebo and then started the drug for the open-label extension.

“It is encouraging to see a drug that both slows the loss of function and lengthens the survival of ALS,” says Stephen Goutman, M.D., director of the Michigan Medicine Pranger ALS Clinic and one of the researchers who led a trial site for the drug. AMX0035 is a combination of sodium phenylbutyrate and taurursodiol.

“It will be important to understand if these benefits extend to all persons with ALS or only those who begin treatment early in disease, as the main trial restricted entry to only those persons within the first 18 months of symptoms.”

Read More

Share this:

  • Facebook
  • Twitter
  • LinkedIn

Filed Under: News

Newsletter Signup

Subscribe to our mailing list for updates regarding our clinic and research

Click Here for the ALS Registry

ALS Center of Excellence at Michigan Medicine ALS Infographic

ALS Brochure

ALS Brochure

 

 

 

 

 

Resources

Organizations

  • ALS Association
  • ALSA-Michigan Chapter
  • Ann Arbor Active Against ALS
  • ALSA-Northern Ohio Chapter
  • ALS of Michigan
  • National ALS Registry
  • Northeast ALS Consortium
  • Muscular Dystrophy Association

Services

  • Veterans Benefits
  • Social Security Benefits

Useful Links

  • U-M Stem Cell Research
  • Center for Stem Cell Biology
  • Human Embryonic Stem Cell Research
  • Society for Stem Cell Research

RSS Research News

  • U-M to establish new Institute for Firearm Injury Prevention
  • U-M Depression Center to be named for Eisenberg family, in recognition of $30M in giving
  • Research on aging expands at U-M with $15M in new grants

Contact Information

Michigan Medicine
1500 E. Medical Center Drive
Ann Arbor, MI 48109
Phone: 734-936-4000
Contact Michigan Medicine

Connect With Us

Copyright © 2023 Regents of the University of Michigan · Disclaimer · Privacy Statement

  • About UMHS
  • For Patients
  • For Health Professionals
  • For Researchers
  • Home
  • About
    ▼
    • What Is ALS?
    • Scott L. Pranger
    • National Advisory Board
    • Faculty & Staff
    • ALS Center of Excellence Brochure
  • Clinic
    ▼
    • Services
    • Your Visit to the ALS Clinic
    • Patient Portal
    • Durable Medical Equipment
    • Frequently Asked Questions
  • Research
    ▼
    • Clinical Trials
    • Observational Studies
    • Participate in Research at U-M
  • News
  • Patient Care Guide
    ▼
    • Living with ALS
    • Nutrition
    • Patient & Family Support
  • Contact
  • NeuroNetwork
  • Make A Gift